Newsletter

NovaBay Pharmaceuticals (NBY) Business Momentum

(Mailing list information, including unsubscription instructions, is located at the end of this message.)

NovaBay Pharmaceuticals, Inc. (NBY)

NBY‘s President and CEO Ron Najafi, Ph.D., will present at the Rodman & Renshaw 17th Annual Global Investment Conference on Thursday, September 10, 2015 at 3:25 p.m. Eastern time (12:25 p.m. Pacific time). The conference is being held at the St. Regis Hotel in New York City.

A live webcast and replay of the company’s presentation will be available on NBY‘s website at http://novabay.com/investors/events.

NBY recently announced that its Avenova(TM), the only lid & lash product containing Neutrox, will be marketed in New Zealand through a partnership with Ophthalmic Instrument Company. NBY‘s Avenova is already in China, Southeast Asia and the Middle East.

Neutrox is NBY‘s proprietary pure hypochlorous acid without any sodium hypochlorite impurities. Hypochlorous acid is naturally produced by white blood cells to fight microbial invaders.

According to NBY, lab tests show that its proprietary formulation of hypochlorous acid is effective in solution both at killing microbes and at neutralizing the bacterial enzymes and toxins that contribute to common eye conditions like blepharitis, meibomian gland dysfunction and associated dry eye

NBY reported second quarter 2015 revenue of $1.0 million, compared to $123,000 in the same period the prior year. NBY said that the increase was due to the sales of Avenova, which was commercially launched in August 2014. NBY‘s Avenova sales increased 73% versus the first quarter of 2015

NBY is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX(TM) Family of Products, cleared by the US FDA as a 510(k) medical device; the NEUTROX Family of Products includes AVENOVA for the eye care market and NEUTROPHASE(R) for wound care, and CELLERX(TM) for the cosmetic surgery and aesthetic dermatology market; and its AGANOCIDE(R) compounds, led by AURICLOSENE(TM) which is in development as a new drug in urology and dermatology.

NBY has partnerships in the U.S. and around the world with PBE, Inc. (U.S.), IHT, Inc. (U.S.), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (South Korea), Biopharm (North African and the Middle East), Sarmedic Ltd (Israel) and Alpha Pharma LLC (the Ukraine).

More about NovaBay Pharmaceuticals, Inc. (NBY) at www.novabay.com

**

Disclaimer: DoubleInStocks (a division of Crown Equity Holdings, Inc.) publishes, distributes information compiled from outside sources. The report/release/advertisement for on this website and on or newsletter and reports such as the company’s stock alerts highlights and advertisements is for general information purposes only. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer ( http://DoubleInStocks.com/disclaimer/ ) is to be read and fully understood before using our site, or joining our email list. Neither DoubleInStocks.com (DoubleInStocks, Crown Equity Holdings, Inc.) nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website (or newsletter) viewing or using you agree to hold DoubleInStocks.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the company profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead, DoubleInStocks.com strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Read full disclaimer at http://DoubleInStocks.com/disclaimer

The following information is a reminder of your current mailing list subscription:

You are subscribed to the following list:

doubleinstocks.com

using the following email:

xxxxxx@gmail.com

You may unsubscribe from this list at any time by visiting the following URL:

http://lists.doubleinstocks.com/dada/mail.cgi/u/stockalerts/xxxxxx/gmail.com/

If the above URL is inoperable, make sure that you have copied the entire address. Some mail readers will wrap a long URL and thus break this automatic unsubscribe mechanism.

You may also change your subscription by visiting this list's main screen:

http://lists.doubleinstocks.com/dada/mail.cgi/list/stockalerts

If you're still having trouble, please contact the list owner at:

stockalerts@doubleinstocks.com

Read our full Disclaimer

The following physical address is associated with this mailing list:

11226 Pentland Downs St Las Vegas, Nevada 89141